相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses
Denise da Rocha Pitta et al.
BMC CANCER (2013)
Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response
Elham O. Hamed et al.
DIAGNOSTIC PATHOLOGY (2013)
Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: Correlation with pathological outcome
M. T. Sandri et al.
GYNECOLOGIC ONCOLOGY (2013)
A comparison between an ultrasound based prediction model (LR2) and the Risk of Ovarian Malignancy Algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass
Jeroen Kaijser et al.
GYNECOLOGIC ONCOLOGY (2013)
The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass
Karen K. L. Chan et al.
GYNECOLOGIC ONCOLOGY (2013)
Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age
Srinivas Kondalsamy-Chennakesavan et al.
GYNECOLOGIC ONCOLOGY (2013)
The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors
Slawomir Lawicki et al.
JOURNAL OF OVARIAN RESEARCH (2013)
The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer
Emanuela Anastasi et al.
JOURNAL OF OVARIAN RESEARCH (2013)
A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses
Cristina Anton et al.
CLINICS (2012)
Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass
Mona Aarenstrup Karlsen et al.
GYNECOLOGIC ONCOLOGY (2012)
Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer
Yongjung Park et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Serum HE4 as a Useful Biomarker in Discriminating Ovarian Cancer From Benign Pelvic Disease
Hong Zheng et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2012)
The Utility of Human Epididymal Protein 4, Cancer Antigen 125, and Risk for Malignancy Algorithm in Ovarian Cancer and Endometriosis
Sasa Kadija et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2012)
Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women
Kevin Holcomb et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2011)
HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm
T. Van Gorp et al.
BRITISH JOURNAL OF CANCER (2011)
Serum Human Epididymis Protein 4 and Risk for Ovarian Malignancy Algorithm as New Diagnostic and Prognostic Tools for Epithelial Ovarian Cancer Management
Elisabetta Bandiera et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2011)
HE4 and epithelial ovarian cancer: Comparison and clinical evaluation of two immunoassays and a combination algorithm
Giuseppina Ruggeri et al.
CLINICA CHIMICA ACTA (2011)
Comparison of Serum Human Epididymis Protein 4 with Cancer Antigen 125 as a Tumor Marker in Patients with Malignant and Nonmalignant Diseases
Jose M. Escudero et al.
CLINICAL CHEMISTRY (2011)
The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?
Martina Montagnana et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2011)
No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting
Francis Jacob et al.
GYNECOLOGIC ONCOLOGY (2011)
Evaluation of the Diagnostic Accuracy of the Risk of Ovarian Malignancy Algorithm in Women With a Pelvic Mass
Richard G. Moore et al.
OBSTETRICS AND GYNECOLOGY (2011)
HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases
Rafael Molina et al.
TUMOR BIOLOGY (2011)
Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass
Brian Nolen et al.
GYNECOLOGIC ONCOLOGY (2010)
HE4: a new potential early biomarker for the recurrence of ovarian cancer
Emanuela Anastasi et al.
TUMOR BIOLOGY (2010)
Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts
K. Huhtinen et al.
BRITISH JOURNAL OF CANCER (2009)
Influence of Ovarian Cancer Risk Status on the Diagnostic Performance of the Serum Biomarkers Mesothelin, HE4, and CA125
Chirag A. Shah et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
Richard G. Moore et al.
GYNECOLOGIC ONCOLOGY (2009)
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass
Richard G. Moore et al.
GYNECOLOGIC ONCOLOGY (2008)
Bivariate random-effects meta-analysis and the estimation of between-study correlation
Richard D. Riley et al.
BMC MEDICAL RESEARCH METHODOLOGY (2007)
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews
JB Reitsma et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2005)
Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometriold ovarian carcinomas
R Drapkin et al.
CANCER RESEARCH (2005)
Use of the concomitant serum dosage of CA 125, CA 19-9 and interleukin-6 to detect the presence of endometriosis.: Results from a series of reproductive age women undergoing laparoscopic surgery for benign gynaecological conditions
E Somigliana et al.
HUMAN REPRODUCTION (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
分享论文
